|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-2-5
|
|
pubmed:abstractText |
We tested whether cyclooxygenase 2 (COX-2) expression and unacetylated COX-1 in newly formed platelets might contribute to persistent thromboxane (TX) biosynthesis in aspirin-treated essential thrombocythemia (ET). Forty-one patients on chronic aspirin (100 mg/day) and 24 healthy subjects were studied. Platelet COX-2 expression was significantly increased in patients and correlated with thiazole orange-positive platelets (r = 0.71, P < .001). The rate of TXA(2) biosynthesis in vivo, as reflected by urinary 11-dehydro-TXB(2) (TXM) excretion, and the maximal biosynthetic capacity of platelets, as reflected by serum TXB(2), were higher in patients compared with aspirin-treated healthy volunteers. Serum TXB(2) was significantly reduced by the selective COX-2 inhibitor NS-398 added in vitro. Patients were randomized to adding the selective COX-2 inhibitor, etoricoxib, or continuing aspirin for 7 days. Etoricoxib significantly reduced by approximately 25% TXM excretion and serum TXB(2). Fourteen of the 41 patients were studied again 21 (+/- 7) months after the first visit. Serum TXB(2) was consistently reduced by approximately 30% by adding NS398 in vitro, while it was completely suppressed with 50 microM aspirin. Accelerated platelet regeneration in most aspirin-treated ET patients may explain aspirin-persistent TXA(2) biosynthesis through enhanced COX-2 activity and faster renewal of unacetylated COX-1. These findings may help in reassessing the optimal antiplatelet strategy in ET.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/11-dehydro-thromboxane B2,
http://linkedlifedata.com/resource/pubmed/chemical/Aspirin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfones,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane A2,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane B2,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxanes,
http://linkedlifedata.com/resource/pubmed/chemical/etoricoxib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
pubmed-author:CiabattoniGiovanniG,
pubmed-author:DavìGiovanniG,
pubmed-author:DraganiAlfredoA,
pubmed-author:FerranteElisabettaE,
pubmed-author:HabibAidaA,
pubmed-author:LattanzioStefanoS,
pubmed-author:MattoscioDomenicoD,
pubmed-author:MucciLucianaL,
pubmed-author:PascaleSilviaS,
pubmed-author:PatronoCarloC,
pubmed-author:PetrucciGiovannaG,
pubmed-author:RanellettiFranco OFO,
pubmed-author:RecchiutiAntonioA,
pubmed-author:RoccaBiancaB
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
4
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1054-61
|
|
pubmed:meshHeading |
pubmed-meshheading:19887674-Adult,
pubmed-meshheading:19887674-Aspirin,
pubmed-meshheading:19887674-Cyclooxygenase 1,
pubmed-meshheading:19887674-Cyclooxygenase 2,
pubmed-meshheading:19887674-Cyclooxygenase Inhibitors,
pubmed-meshheading:19887674-Drug Therapy, Combination,
pubmed-meshheading:19887674-Female,
pubmed-meshheading:19887674-Humans,
pubmed-meshheading:19887674-Immunohistochemistry,
pubmed-meshheading:19887674-Male,
pubmed-meshheading:19887674-Middle Aged,
pubmed-meshheading:19887674-Platelet Aggregation Inhibitors,
pubmed-meshheading:19887674-Pyridines,
pubmed-meshheading:19887674-Sulfones,
pubmed-meshheading:19887674-Thrombocythemia, Essential,
pubmed-meshheading:19887674-Thromboxane A2,
pubmed-meshheading:19887674-Thromboxane B2,
pubmed-meshheading:19887674-Thromboxanes,
pubmed-meshheading:19887674-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.
|
|
pubmed:affiliation |
Department of Hematology, Spirito Santo Hospital, Pescara, Italy.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
